Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer

Genetic alterations in RET lead to activation of ERK and AKT signaling and are associated with hereditary and sporadic thyroid cancer and lung cancer. Highly selective RET inhibitors have recently entered clinical use after demonstrating efficacy in treating patients with diverse tumor types harboring RET gene rearrangements or activating mutations. In order to understand resistance mechanisms arising after treatment with RET inhibitors, we performed a comprehensive molecular and genomic analysis of a patient with RET-rearranged thyroid cancer. Using a combination of drug screening and proteomic and biochemical profiling, we identified an adaptive resistance to RET inhibitors that reactivates ERK signaling within hours of drug exposure. We found that activation of FGFR signaling is a mechanism of adaptive resistance to RET inhibitors that activates ERK signaling. Combined inhibition of FGFR and RET prevented the development of adaptive resistance to RET inhibitors, reduced cell viability, and decreased tumor growth in cellular and animal models of CCDC6-RET–rearranged thyroid cancer.

[1]  B. Taylor,et al.  Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib , 2020, Clinical Cancer Research.

[2]  A. Drilon,et al.  Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. , 2020, The New England journal of medicine.

[3]  A. Drilon,et al.  Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[4]  R. Madison,et al.  Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  N. Rosen,et al.  EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. , 2020, Cancer discovery.

[6]  Shalini C. Pereira,et al.  Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy , 2020, Clinical Cancer Research.

[7]  M. Santoro,et al.  RET Gene Fusions in Malignancies of the Thyroid and Other Tissues , 2020, Genes.

[8]  A. Drilon,et al.  RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Neil Vasan,et al.  A view on drug resistance in cancer , 2019, Nature.

[10]  Harpreet Wasan,et al.  Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2019, The New England journal of medicine.

[11]  J. Vilo,et al.  g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) , 2019, Nucleic Acids Res..

[12]  R. Sachidanandam,et al.  SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors , 2019, Cell reports.

[13]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[14]  A. Shaw,et al.  Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  B. Neel,et al.  SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. , 2018, Cancer discovery.

[16]  Li Ding,et al.  Driver Fusions and Their Implications in the Development and Treatment of Human Cancers , 2018, Cell reports.

[17]  M. Lawrence,et al.  SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors , 2018, Nature Medicine.

[18]  C. Azzoli,et al.  Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. , 2017, Translational lung cancer research.

[19]  P. Jänne,et al.  Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer , 2017, ESMO Open.

[20]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.

[21]  A. Drilon,et al.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.

[22]  O. Elemento,et al.  Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression , 2017, eLife.

[23]  R. Cagan,et al.  Drosophila Cancer Models Identify Functional Differences between Ret Fusions. , 2016, Cell reports.

[24]  Sarah L. Williams,et al.  Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. , 2016, Journal of medicinal chemistry.

[25]  Ping Zhu,et al.  Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases , 2016, Nature.

[26]  C. Sander,et al.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2016, The Journal of clinical investigation.

[27]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[28]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[29]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[30]  M. Brose,et al.  A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. , 2014, Thyroid : official journal of the American Thyroid Association.

[31]  René Bernards,et al.  Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. , 2014, Trends in biochemical sciences.

[32]  Andreas Schlicker,et al.  Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.

[33]  M. Santoro,et al.  Central role of RET in thyroid cancer. , 2013, Cold Spring Harbor perspectives in biology.

[34]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Bishop,et al.  Highly prevalent TERT promoter mutations in aggressive thyroid cancers. , 2013, Endocrine-related cancer.

[36]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[37]  S. Chandarlapaty,et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.

[38]  Carlotta Costa,et al.  MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.

[39]  Sarat Chandarlapaty,et al.  Negative feedback and adaptive resistance to the targeted therapy of cancer. , 2012, Cancer discovery.

[40]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[41]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[42]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[43]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[44]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[45]  Pascal Furet,et al.  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. , 2011, Journal of medicinal chemistry.

[46]  R. Jove,et al.  The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival , 2011, Leukemia.

[47]  Edward L. Huttlin,et al.  A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression , 2010, Cell.

[48]  J. Heath,et al.  Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. , 2010, Cancer research.

[49]  D. Pfister,et al.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[51]  C. Capen,et al.  Genetic Alterations in Thyroid Cancer: The Role of Mouse Models , 2007, Veterinary pathology.

[52]  L. Scapozza,et al.  Inhibition of RET tyrosine kinase by SU5416. , 2006, Journal of molecular endocrinology.

[53]  Steven P Gygi,et al.  A probability-based approach for high-throughput protein phosphorylation analysis and site localization , 2006, Nature Biotechnology.

[54]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  I. Lax,et al.  The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. , 2002, Molecular cell.

[56]  G. Chiappetta,et al.  Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. , 2002, The American journal of pathology.

[57]  M. Santoro,et al.  Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade , 2001, Molecular and Cellular Biology.

[58]  Matthew Freeman,et al.  Sprouty, an Intracellular Inhibitor of Ras Signaling , 1999, Cell.

[59]  A. Ashworth,et al.  Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54jnk. , 1995, Oncogene.

[60]  A. Knuth,et al.  Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines. , 1995, Cancer genetics and cytogenetics.

[61]  Kun-Liang Guan,et al.  Isolation and Characterization of a Novel Dual Specific Phosphatase, HVH2, Which Selectively Dephosphorylates the Mitogen-activated Protein Kinase (*) , 1995, The Journal of Biological Chemistry.

[62]  Charis Eng,et al.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling , 1995, Nature.

[63]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[64]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[65]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[66]  M. Santoro,et al.  PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.

[67]  T. Sugimura,et al.  Presence of Aberrant Transcripts of ret Proto‐oncogene in a Human Papillary Thyroid Carcinoma Cell Line , 1989, Japanese journal of cancer research : Gann.